InvestorsHub Logo
Followers 234
Posts 26887
Boards Moderated 0
Alias Born 01/12/2013

Re: couldbebetter post# 115643

Saturday, 10/07/2017 9:16:22 AM

Saturday, October 07, 2017 9:16:22 AM

Post# of 426047
Hi CB- A.fib while it can be a "side effect" of DHA is generally a more survivable disease state than NASH. So under the assumption of risk this could be a viable alternative for Epanova as opposed to competing with "V' for the cardiovascular space.

I think it's a very bad idea for AZN to attempt to "win" market share for the cardiovascular space with Epanova due to the massive diarrhea side effects which would most definitely decrease patient compliance; increasing cardiovascular overall expense for the entire healthcare system is counterproductive.

BB

Mr. McGee, don't make me angry. You wouldn't like me when I'm angry---David Banner

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News